Back to Newsroom

Data from Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody against CGRP for the Prevention of Migraine, to be Presented at American Academy of Neurology Meeting

BOTHELL, Wash., April 23rd , 2014 – Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King’s College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-concept clinical trial of ALD403 for the prevention of frequent episodic migraine at the American Academy of Neurology Meeting, Friday, May 2, in Philadelphia, Pennsylvania.

Click here to read more